In 2026, R&D speed is about learning faster, scaling responsibly and reducing risk in an increasingly complex system, says ...

Fast-tracked psychedelics hit a wall: why the FDA’s pause on psilocybin is an important check to ensure safety, rigor, and long-term evidence before the drugs reach patients.

The beetle’s white exoskeleton is made from a compound called chitin, which is a type of carbohydrate – one that is also ...

A landmark paper published in Lancet Psychiatry—the largest-ever review of the safety and efficacy of cannabinoids across a ...

BaRupOn Healthcare integrates pharmacy, distribution, and biomedical innovation to strengthen U.S. healthcare supply ...

When reviewing a 75+ page consumer loan sale agreement, you slow-pedal some provisions and fast-pedal others. You’re more focused on the ...

A landmark Lancet Psychiatry paper published today has found no evidence that medicinal cannabis is effective in treating anxiety, depression or post-traumatic stress disorder (PTSD).

Springtime in Pennsylvania is peanut butter egg season. This year some consumers may taste the eggs a bit more critically and scrutinize the ingredients and label more carefully. Reese’s, a Hershey ...

But as these products proliferate, manufacturers face a new set of questions. How do expectations around comfort, usability, ...

Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, ...

Assertio Holdings, Inc. (NASDAQ:ASRT) Q4 2025 Earnings Call Transcript March 16, 2026 Assertio Holdings, Inc. beats earnings expectations. Reported EPS is $-1.72227, expectations were $-3.1225.